Researchers at Sahlgrenska Academy, in Gothenburg, Sweden, have finalized the pivotal clinical pharmacokinetic trial where Infudopa SubC™ and Infudopa IntraV™ have been compared with Duodopa®/Duopa® with respect to serum levodopa levels in 18 patients with late stage Parkinson´s disease. Dizlin Pharmaceuticals expect analyzed data in H2 2020.